Cerus (CERS) Stock Price, News & Analysis

Company Overview

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products. Cerus also offers research tool products that enable academic and industrial laboratories to study pathogen inactivation mechanisms and develop further applications of its technology. These tools support investigators in exploring blood safety challenges and advancing transfusion medicine research.

Founded in 1991 and headquartered in Concord, California, Cerus has secured regulatory approvals and clearances in multiple markets, including the United States, Europe, Asia-Pacific, and Latin America. Its products are deployed by blood establishments and hospitals across more than 20 countries, where they contribute to improving patient outcomes and supporting public health initiatives.

Cerus continues to advance its pipeline with programs targeting pathogen reduction for red blood cells and novel formulations to address emerging infectious threats. The company is led by a management team with extensive experience in biotechnology, transfusion medicine, and regulatory affairs, positioning it to expand the reach of its technology and drive ongoing innovation in blood safety.

Key Stats

• Today's Range: $2.48 to $2.66
• 50-Day Range: $1.69 to $2.61
• 52-Week Range: $1.15 to $3.15
• Volume: 1.07 million shs
• Average Volume: 1.88 million shs
• Market Capitalization: $519.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

Cerus Stock Analysis - MarketRank™

Cerus scored higher than 51% of companies evaluated by MarketBeat, and ranked 448th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

Cerus has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Cerus has a consensus price target of $4.00, representing about 55.8% upside from its current price of $2.57.

Amount of Analyst Coverage

Cerus has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cerus are expected to grow in the coming year, from ($0.02) to $0.03 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cerus is -51.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cerus is -51.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cerus has a P/B Ratio of 7.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.18% of the float of Cerus has been sold short.

Short Interest Ratio / Days to Cover

Cerus has a short interest ratio ("days to cover") of 12.45, which indicates bearish sentiment.

Change versus previous month

Short interest in Cerus has recently increased by 0.77%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cerus does not currently pay a dividend.

Dividend Growth

Cerus does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.65

News Sentiment

Cerus has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Cerus this week, compared to 3 articles on an average week.

Search Interest

6 people have searched for CERS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Cerus to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cerus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,156,291.00 in company stock.

Percentage Held by Insiders

5.60% of the stock of Cerus is held by insiders.

Percentage Held by Institutions

78.37% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 4/30/2026
• Today: 5/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Supplies
• Current Symbol: NASDAQ:CERS
• CIK: 1020214
• Web: www.cerus.com
• Phone: (925) 288-6000
• Fax: 925-288-6001
• Employees: 290
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Cerus: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +55.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.63 million
• Net Margins: -4.41%
• Pretax Margin: -4.25%
• Return on Equity: -15.18%
• Return on Assets: -4.38%

Debt

• Debt-to-Equity Ratio: 0.47
• Current Ratio: 1.63
• Quick Ratio: 1.06

Sales & Book Value

• Annual Sales: $206.13 million
• Price / Sales: 2.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.34 per share
• Price / Book: 7.57

Miscellaneous

• Outstanding Shares: 200,370,000
• Free Float: 189,148,000
• Market Cap: $515.95 million
• Optionable: Optionable
• Beta: 1.62